NCT01978301View on ClinicalTrials.gov

Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 15, 2014

Primary Completion Date

February 5, 2015

Study Completion Date

February 5, 2015

Conditions
Fibrosis
Interventions
DRUG

Triamcinolone acetonide

Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).

DRUG

Placebo

Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).

Trial Locations (1)

E1 2AT

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01978301 - Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars | Biotech Hunter | Biotech Hunter